Arch Biopartners (TSXV:ARCH) Net Issuance of Preferred Stock : C$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Arch Biopartners's net issuance of preferred for the three months ended in Dec. 2023 was C$0.00 Mil. The number is 0, which means that Arch Biopartners has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Arch Biopartners's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2023 was C$0.00 Mil.

Arch Biopartners Net Issuance of Preferred Stock Historical Data

The historical data trend for Arch Biopartners's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Net Issuance of Preferred Stock Chart

Arch Biopartners Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Arch Biopartners Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Arch Biopartners Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Arch Biopartners Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Arch Biopartners's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Arch Biopartners (TSXV:ARCH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

545 King Street West, Toronto, ON, CAN, M5V 1M1

Website

https://www.archbiopartners.com

Arch Biopartners Inc is a clinical stage company developing technologies with the potential to make medical or commercial impacts. The company is developing a drug platform Metablok to produce drug candidates to inhibit organ inflammation caused via the DPEP-1 pathway. It's under development portfolio is AB569, a potential new treatment for antibiotic resistant bacterial infections in the lungs or wounds; and, Borg peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.